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Autoimmune diseases comprise a large, diverse group
of diseases characterized by a humoral or cell-mediated
immune response against the constituents of the body's
own tissues. In cases in which the host is sensitized with
a tissue-specific antigen, a single pathological immune
reaction occurs in the target organ. In those cases in
which the host is sensitized with either a single tissue
nonspecific or many tissue-specific antigens, several
pathological immune reactions occur in many target or-
gans. Examples bf each type of autoimmune disease are
shown in Tables 1 and 2. This classification is arbitrary,
and in certain patients a combination of immunological
reactions may be detected. Furthermore, what is consid-
ered organ-specific presently may turn out to be multior-
gan diseases in the future.
Within the organ-specific autoimmune diseases, there
is a group (Table 3) of diseases in which the patients
produce autoantibodies directed against different cell
surface receptors.'"^ Autoantibodies will bind these cell
surface receptors and impair their physiologic function.
The common feature to all these diseases is the cross-
linking of cell surface receptors, which occurs after bind-
ing the autoantibody.^ Moreover, this immunological
reaction increases the metabolic degradation of these
receptors. Abnormal receptor function may result from
receptor blockade or decrease in the number of recep-
tors available due to increased degradation of these
molecules. In some cases, the autoantibody has been
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shown to possess activity somewhat similar to the recep-
tor involved; for example, insulin-like activity for au-
toantibodies against insulin-receptor.® Although experi-
mental evidence is not available as yet, it is tempting to
speculate that pemphigus autoantibodies also bind to
epidermal cell surface receptors important in cell-to-cell
adhesion. It has been shown that pemphigus autoan-
tibodies induce acantholysis^ or epidermal cell de-
tachment*'* when tested in vitro.
The autoimmune diseases shown in Tables 1 and 2
share two common pathogenetic mechanisms, ie, one, a
loss of self-tolerance, and two, the activation of B or T
cells. The result of these defects is the induction of a
hypersensitivity state. The hypersensitivity states have
been classified into four major types.'" There may be in
situ antigen-antibody reactions with complement activa-
tion, which leads to tissue damage (Type II). Antigen-
antibody complexes may also circulate as immune
complexes and become trapped in various organs result-
ing in complement activation and tissue damage (Type
III). This mechanism is thought to be responsbile for the
renal disease and vasculitis seen in systemic lupus ery-
thematosus. T-cells may alone become activated, lead-
ing to a delayed-type hypersensitivity reaction (Type IV),
as may be found in Hashimoto's thyroiditls.
Tolerance to Self-antigens
Immune tolerance may be thought of as a homeostatic
mechanism maintained by the interaction of the immune
system and the host antigens. When this homeostasis is
broken, the immune system is activated, resulting in
reactions against host antigens and causing disease. This
is the "Horror Autotoxicus" described by Ehrlich at the
turn of the century." Immune tolerance is an incom-
pletely understood mechanism whereby the immune
system of an animal recognizes self-antigens and re-
mains unresponsive to them. Tolerance involves a gene-
tic endowment, a long-lasting immunological memory
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toward self-antigens after fetal exposure and active im-
munological mechanisms that protect the animal from
responding against self. Tolerance may be defined as an
antigen-specific immunological unresponsiveness,
either cell-mediated or humoral of a host animal; to an
antigen to which it would otherwise respond.
One of the earliest theories of tolerance was proposed
by Jerne in 1955.'^ He postulated that preformed anti-
body was present in the fetus prior to postembryonic
antigenic stimulation. Animals exposed to antigens after
birth will develop proliferating antibody producing cells,
specific for the immunizing antigen. Antibodies that
react with self-antigens will be eliminated.
The theory of clonal selection was introduced by Bur-
net in 1959." He proposed that contact of lymphocytes
with self-antigens during fetal life (or for a short time
after birth) would lead to the destruction and elimination
of those clones that would be autoreactive. Another term
that he proposed for this process was "functional elimi-
nation." Self-lymphocytes sensitized to self-antigens are
destroyed, rendering the hosts unable to respond to their
own tissue antigens. This theory is generally accepted
presently, although it does have some unanswered ob-
servations. It is known, for example, that circulating au-
toantibodies against self-antigens may be detected under
normal conditions, ie, autoantibodies against
thyroglobulin.
Other theories have been discussed to explain im-
mune tolerance. Extensive cross-linking of cell surface
receptors for antigen, induced by the tolerogen will in-
duce unresponsiveness of the cells involved in the im-
mune response. Other investigators believe that normal
serum contains blocking factors, perhaps immune com-
plexes, which abrogate the immune response to anti-
gens. Finally, the modulation of the immune response
and tolerance toward self- and nonself-antigens may be
one of the functions of suppressor T-cells.

















Although the exact mechanism of immunological
tolerance remains unknown, there are some basic prin-
ciples already confirmed experimentally. These are: (1)
Tolerance is learned by the immune system. Immune
tolerance is an acquired trait, and is not strictly a genetic
phenomenon. This was shown by Owen in 1945 in ex-
periments with chimeric calves, having fetal cross-
circulation and mutual tolerance to blood groups and
skin grafts." (2) Tolerance is easier to induce in young
animals. The younger an animal is, the easier it is to
tolerize. (3) High doses of antigen induce tolerance,
whereas low doses are immunogenic. Likewise, some
antigens may display both low-dose and high-dose tol-
erance, and in some animals, multiple small doses of
antigen will induce tolerance. (4) Tolerance is separate
and distinct for the T and B arms of the immune system.
It is extremely difficult to induce and maintain B-cell
tolerance requiring 10-100 times the usual dose of anti-
gens for immunization. Tolerance is usually short-lived.
The T-cell system is tolerized at low doses of antigen,
and also at extremely high doses of antigen. The low-
dose tolerance may be related to the generation of
specific suppressor T-cells. High-dose tolerance is due to
an immunological overload of antigen and a "freezing"
of all antigen-specific responses of T and B cells and
hence, unresponsiveness.
Animal Models of Autoimmunity
The basic defects that may cause the break in toler-
ance leading to disease states have come from the study
of animal models. The best known model of multisystem
autoimmune disease is the New Zealand mouse derived
from a strain taken to Australia for cancer research in
1959.'^ This strain has the following general
features*"'": (1) early immunologic maturation; (2)
humoral hyper-responsiveness early in life; (3) loss of
tolerance to foreign and self-antigens early in life; (4)
impaired cell-mediated immunity late in life; (5) loss of
recirculating thymocytes; (6) loss of thymic-derived
suppressor activity; (7) spontaneous production of
antithymocyte antibodies; and (8) spontaneous devel-
opment of circulating immune complexes, including
antibodies to DNA.
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Two inbred colonies derived from the New Zealand
mice have been studied in detail. One is the NZB/NZB
cross, that is a model of autoimmune hemolytic anemia
and has the following features^*: (1) autoimmune
hemolytic anemia early in life leading to reticulocytosis
and splenomegaly later in life; (2) low incidence of both
ANA and positive LE preparations; (3) development of
glomerulonephritis late in life; and (4) cytotoxic IgM an-
tibodies for T-cells. The other mouse colony is the
NZB/NZW F, generation. These mice show features
similar to human systemic lupus erythematosus.'^ These
are: (1) high incidence of both ANA and LE preparation;
(2) severe immune-complex glomerulonephritis; (3) low
levels of antibodies to erythrocytes and thymocytes; (4)
high antibody titer to both DNA and RNA; and (5) a
more severe disease found in female mice.
Dermatological Models of Autoimmunity
There are dermatological diseases that are examples
of organ-specific and organ nonspecific autoimmune
diseases. Organ-specific models would include pem-
phigus vulgaris and bullous pemphigoid; these diseases
show a highly specific autoimmune reaction directed
against the skin. Pemphigus vulgaris is a disease in
which there is an autoantibody to a cell surface glyco-
protein of differentiating keratinocytes. Normal individu-
als are tolerant to this epidermal antigen. If tolerance to
this antigen is lost, patients will manufacture pathogenic
antiepidermal antibodies. Bullous pemphigoid is
another highly specific autoimmune dermatological dis-
ease. These patients become sensitized to an antigen
normally found at the cutaneous basement zone (BMZ)
and produce anti-BMZ autoantibodies. Like in pem-
phigus vulgaris, these patients have lost their immune
tolerance to this self-antigen.
The organ nonspecific autoimmune diseases are best
represented by systemic lupus erythematosus. Many
antigen-antibody systems have been detected in the sera
of those patients involving DNA, RNA, RNP, Sm, Ro, La,
etc. There are many reviews dealing with this subject
already published in this and other journals.'*"^^ Other
organ nonspecific autoimmune diseases are der-
matomyositis, Sjogren's syndrome, and scleroderma,
where the antigenic components are not well defined.
Autoimmune Diseases—Pathogenesis
Numerous theories have been proposed to explain the
development of autoimmunity in experimental animals
and man. Some of these theories are similar and overlap
in a spectrum. Since most of these entities are so diverse
and variable, it is difficult to select a unifying theory to
link the spectrum of autoimmunity. Here we will restrict
our discussion to what appears to be the most important
factors in the pathogenesis of the autoimmune diseases.
Genetic Factors
The genetic control of the immune response must be
considered in the pathogenesis of autoimmunity. Rec-
ognition and processing of antigens by the immune
system of an animal is a genetically controlled mech-
anism.̂ '' For example, in man the major histocompatibil-
ity complex, also called the HLA system, controls the
synthesis of cell surface molecules grouped in four loci:
HLA-A, HLA-B, HLA-C, and HLA-D. These molecules,
which are phenotypic products of the major histocom-
patibility complex, can be identified in vitro. Any indi-
vidual may be typed according to their HLA haplotype.
Recent work has demonstrated the importance of var-
ious HLA genes that control the immune response (Ir
genes), or predispose to disease susceptibility. Many as-
sociations of diseases with certain HLA typings have
been described, but the most impressive are in the
HLA-A8 and HLA-B27 loci. HLA-A8 is increased in
young females with myasthenia gravis. Graves' disease,
and insulin-resistant diabetes.̂ ^~^* A high incidence of
HLA-B27 haplotype is seen in patients with Reiter's syn-
drome, juvenile rheumatoid arthritis, and ankylosing
spondylitis.^^ Pemphigus vulgaris also has a high associ-
ation with HLA-DRW4 in the Jewish population,^*
whereas bullous pemphigoid and lupus erythematosus
show no consistent HLA associations.
A genetic hypothesis to explain the autoimmune
phenomenon found in patients with systemic lupus ery-
thematosus has been proposed by Ouimby and
Schwartz.^* According to these authors, a set of genes
will make the host animal predisposed to develop au-
toimmunity, and another set of genes will confer the
phenotype characteristics to the autoimmune disease.
Both classes of genes would consist of multiple unlinked
dominant and recessive components with structural and
modifier genes possible in both classes.
Viral Factors
A viral theory for the development of autoimmunity
has been described previously.^" A virus may trigger au-
toimmunity by different mechanisms. Some of these may
involve the nonspecific polyclonal stimulation of B-cells
with a resulting overproduction of antibodies and au-
toantibodies.^' In other cases, the virus may combine
with the host DNA and be expressed on the surface of
infected cells. These neoantigens may sensitize the
host's immune system to respond to both self and viral
antigens. Neoantigens can also be formed by conjuga-
tion of viral and host cell coats as shown by Burns and
Allison.^^ It is known that C-type viral particles are found
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in many organs of New Zealand mice and the kidneys of
patients with lupus erythematosus.̂ -̂̂ ^ It is conceivable
that these viral particles may be present but not causally
related to the pathogenesis of the disease.
Adjuvants and Bacterial Injections
Adjuvants and bacterial infections may also play an
important role in the pathogenesis of autoimmune dis-
eases. Nonspecific polyclonal activators such as Es-
cherichia lipopolysaccharide or tuberculin may stimu-
late B-cells to produce antibodies, escaping normal
regulatory control mechanisms.^'' Complete Freund's
adjuvant is a nonspecific activator of T-cells.^''
Bacterial infections, especially the chronic type, may
be the source of substances that may act as polyclonal
activators or adjuvants in the induction of autoimmune
disease. Furthermore, self and bacterial antigens may
cross react and consequently trigger the autoimmune
reaction as seen in rheumatic heart disease.̂ ^"''"'
Suppressor T-cells
Thymus derived lymphocytes constitute a functionally
heterogeneous population of cells. Some T-cells provide
helper functions for B-cell activation, another suppresses
B-and T-cell activation and finally a group capable of
directly killing target cells.^'"^* Abrogation of some of
these subpopulation of T-lymphocytes may originate
and perpetuate autoimmune reactions against self-
antigens. For example, lack of suppressor T-cells that
modulate B-cell activation may lead to the overproduc-
tion of autoantibodies. Recent studies^ "̂"*̂  have shown
that peripheral blood lymphocytes from patients with
SLE or juvenile RA are unable to generate suppressor
T-cell function in vitro. It is unknown whether this defect
in suppressor T-cell has a primary or secondary relation
to the autoimmune reactions present in these patients.
Antilymphocyte Antibodies
Lymphocytes from patients with active SLE show a
low or absent suppressor activity and a poor mixed
lymphocyte reaction response when tested in vitro."*^
This defect may result from the cytotoxic effect of circu-
lating autoantibodies. Several reports have showri that
the serum of patients with SLE eliminates suppressor
T-cell functions from peripheral blood lymphocytes of...
normal individuals.'"'-''^ This cytotoxic serum factor can
be absorbed out using T-cells but not with non-T-cells.
Furthermore, this factor has been identified in both IgG
and IgM immunoglobulin classes.
Other Theories of Autoimmunity
Drugs or degradation products of self-antigens may
bind to tissue constituents forming a hapten-carrier
complex which then triggers autoimmunity.''""''^ Drugs
inducing lupus-like syndromes or hemolytic anemia are
well documented in the clinical literature.''"-''* In some
cases, self-antigens, are sequestered from the immune
system by a biological barrier-membrane. If the permea-
bility of this membrane is altered, active sensitization
and autoimmunity may occur,'"' eg, encephalomyelitis
triggered by sensitization to myelin basic protein, or or-
chitis due to autosensitization to sperm.
Defects in thymic hormones,^'''^' thymus atrophy,'̂ ^ or
faulty antigen-processing by macrophages '̂* as the cause
of autoimmunity are postulated by some investigators.
Finally some authors^''-^" think that autoimmunity may
result from disturbances in the equilibrium between
idiotypes and anti-idiotype antibodies present in the host
animal.
Summary
Autoimmune diseases are entities in which the host
becomes sensitized to self-antigens mounting a humoral
and/or cell-mediated immune response to target tissues.
The basic defect in all autoimmune diseases is man-
ifested by loss of immune tolerance to self-antigens. Im-
mune tolerance under normal conditions is a complex
biological phenomenon not fully understood as yet.
Many theories to explain autoimmunity have been pos-
tulated. In an individual patient, however, many of these
theories may be found to be correct. Dermatological
research is just beginning to explore this area using der-
matologic organ-specific autoimmune diseases as ex-
perimental models.
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